← Back to Search

Fermented Foods Diet for Ulcerative Colitis

N/A
Recruiting
Led By Sidhartha Sinha, MD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Confirmed diagnosis of UC
Symptomatic disease defined as partial Mayo Score 2 to 7 (inclusive)
Must not have
Women who are pregnant, nursing or expect to be pregnant
Individuals with history of severe cardiac disease (particularly uncompensated congestive heart failure NYHA grade 2 or more or LVEF < 40%)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (data collection 1) versus week 10 (data collection 2).

Summary

This trial will test if a diet rich in fermented foods can help improve symptoms and quality of life in people with UC.

Who is the study for?
This trial is for men and women over 18 with mild to moderate Ulcerative Colitis (UC), confirmed by diagnosis. Participants must have symptoms, shown by a partial Mayo Score of 2-7, and elevated fecal calprotectin levels. They need to give written consent to join.
What is being tested?
The study aims to understand the impact of a diet supplemented with fermented foods on inflammation and life quality in UC patients compared to those on a regular diet. It explores how these foods might affect gut health and inflammatory responses.
What are the potential side effects?
While not explicitly listed, potential side effects may include changes in digestion or discomfort due to dietary adjustments. Fermented foods can sometimes cause bloating or gas as the body adapts.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with ulcerative colitis.
Select...
My symptoms are moderate, based on a specific score.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently pregnant, nursing, or planning to become pregnant.
Select...
I do not have severe heart disease, such as heart failure worse than NYHA grade 1 or a left ventricular ejection fraction less than 40%.
Select...
I have had major surgery on my intestines.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (data collection 1) versus week 10 (data collection 2).
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (data collection 1) versus week 10 (data collection 2). for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in the clinical disease activity inflammatory marker fecal calprotectin
Secondary study objectives
Changes in cytokines/chemokines and immune cell profiles
Changes in gut microbiome profiles
Clinical remission as per partial Mayo score.
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Fermented Food-Supplemented DietExperimental Treatment1 Intervention
Patients in this arm will supplement their regular diet by an increasing number of daily servings of fermented food over a period of 10 weeks.
Group II: Regular Diet Control ArmPlacebo Group1 Intervention
Patients in this arm will continue their regular diet throughout the 10 weeks of study with a maximum of 1 serving of fermented foods per day.

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,469 Previous Clinical Trials
17,496,542 Total Patients Enrolled
Sidhartha Sinha, MDPrincipal InvestigatorStanford University
4 Previous Clinical Trials
184 Total Patients Enrolled

Media Library

Fermented Food-supplemented Diet Clinical Trial Eligibility Overview. Trial Name: NCT04401605 — N/A
Inflammatory Bowel Disease Research Study Groups: Fermented Food-Supplemented Diet, Regular Diet Control Arm
Inflammatory Bowel Disease Clinical Trial 2023: Fermented Food-supplemented Diet Highlights & Side Effects. Trial Name: NCT04401605 — N/A
Fermented Food-supplemented Diet 2023 Treatment Timeline for Medical Study. Trial Name: NCT04401605 — N/A
~4 spots leftby Nov 2025